0001867096-23-000117.txt : 20230809
0001867096-23-000117.hdr.sgml : 20230809
20230809185708
ACCESSION NUMBER: 0001867096-23-000117
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230809
FILED AS OF DATE: 20230809
DATE AS OF CHANGE: 20230809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Edick Paul R
CENTRAL INDEX KEY: 0001531178
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 231156686
MAIL ADDRESS:
STREET 1: C/O NEWLINK GENETICS CORP.
STREET 2: 2503 SOUTH LOOP DR., SUITE 5100
CITY: AMES
STATE: IA
ZIP: 50010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
wk-form4_1691621818.xml
FORM 4
X0508
4
2023-08-09
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001531178
Edick Paul R
C/O XERIS BIOPHARMA HOLDINGS, INC.
1375 WEST FULTON STREET, SUITE 1300
CHICAGO
IL
60607
1
1
0
0
See Remarks
0
Common Stock
2023-08-09
4
P
0
10000
2.3794
A
2288064
D
Common Stock
33430
I
By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.365 to $2.3899, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Chairman and Chief Executive Officer
/s/ Beth Hecht as Attorney-in-Fact
2023-08-09